Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer
Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to t...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | Journal of Traditional Chinese Medical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095754821000442 |
id |
doaj-7252d3e2ffe44d9b8a836564a1e18de3 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kaiqi Liu Hongliang Li Jufeng Duan Xiaojing Chen Xiongjie Yu Xianhe Wang Ming Liu Bei Li Minglun Li Yibin Feng Xiaojun Cai Xuanbin Wang |
spellingShingle |
Kaiqi Liu Hongliang Li Jufeng Duan Xiaojing Chen Xiongjie Yu Xianhe Wang Ming Liu Bei Li Minglun Li Yibin Feng Xiaojun Cai Xuanbin Wang Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer Journal of Traditional Chinese Medical Sciences Traditional Chinese medicines Primary liver cancer Integrative medicine Clinical research |
author_facet |
Kaiqi Liu Hongliang Li Jufeng Duan Xiaojing Chen Xiongjie Yu Xianhe Wang Ming Liu Bei Li Minglun Li Yibin Feng Xiaojun Cai Xuanbin Wang |
author_sort |
Kaiqi Liu |
title |
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer |
title_short |
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer |
title_full |
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer |
title_fullStr |
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer |
title_full_unstemmed |
Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancer |
title_sort |
progress in clinical research on the integration of chinese and western medicines for treating primary liver cancer |
publisher |
Elsevier |
series |
Journal of Traditional Chinese Medical Sciences |
issn |
2095-7548 |
publishDate |
2021-07-01 |
description |
Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to treat a variety of diseases, including liver diseases, for more than 2000 years. In this study, we performed a review of the use frequency and clinical efficacy of TCM in treating PLC. Relevant literature from January 1, 2009, to January 1, 2021 was retrieved from network databases of China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, PubMed, and SinoMed. The most frequently used TCM and their efficacy in PLC treatment were summarized. Based on the inclusion and exclusion criteria, 33 articles were selected. Overall, the efficacy of the combination of TCM and Western medicines in the treatment of PLC was higher than that in the control groups (i.e. treatment with Western medicines alone) (65.11% vs. 44.31%, P < .05). Among the 33 selected articles, 11 were investigated for TCM preparation (marketed drugs) and 22 for TCM formulas. In total, 102 types of TCM (single herbs) were used to treat PLC. The top five most frequently used TCM were Poria (14.71%), Astragali radix (13.73%), Atractylodis Macrocephalae Rhizoma (12.75%), Bupleuri radix (12.75%), and Glycyrrhizae radix et Rhizoma (11.76%). Of the 102 types of TCM, tonics were the most frequently used categories, followed by heat-clearing medicines, blood-invigorating medicines, and stasis-resolving medicines. Of 207 papers, 174 (84.06%) could not be subjected to statistical analysis due to research quality. Further high-quality research on herb sources, formula components and dosage, toxicology, and ethics of TCM is necessary. In conclusion, TCM play a promising role in the treatment and management of PLC, although further investigations are warranted. |
topic |
Traditional Chinese medicines Primary liver cancer Integrative medicine Clinical research |
url |
http://www.sciencedirect.com/science/article/pii/S2095754821000442 |
work_keys_str_mv |
AT kaiqiliu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT hongliangli progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT jufengduan progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT xiaojingchen progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT xiongjieyu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT xianhewang progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT mingliu progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT beili progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT minglunli progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT yibinfeng progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT xiaojuncai progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer AT xuanbinwang progressinclinicalresearchontheintegrationofchineseandwesternmedicinesfortreatingprimarylivercancer |
_version_ |
1721206101445181440 |
spelling |
doaj-7252d3e2ffe44d9b8a836564a1e18de32021-08-16T04:16:24ZengElsevierJournal of Traditional Chinese Medical Sciences2095-75482021-07-0183173185Progress in clinical research on the integration of Chinese and Western medicines for treating primary liver cancerKaiqi Liu0Hongliang Li1Jufeng Duan2Xiaojing Chen3Xiongjie Yu4Xianhe Wang5Ming Liu6Bei Li7Minglun Li8Yibin Feng9Xiaojun Cai10Xuanbin Wang11Laboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaBiomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, 442000, ChinaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, GermanySchool of Chinese Medicine, The University of Hong Kong, Hong Kong, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, ChinaLaboratory of Chinese Herbal Pharmacology, Oncology Center, Renmin Hospital; School of Pharmacy, Hubei University of Medicine, Shiyan, 442000, China; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, 442000, China; Corresponding author.Primary liver cancer (PLC) is one of the most common malignant tumors in China. PLC is characterized by insidious onset, rapid progress, poor quality of life, and short survival time. Notably, current treatment strategies remain unsatisfactory. Traditional Chinese medicines (TCM) have been used to treat a variety of diseases, including liver diseases, for more than 2000 years. In this study, we performed a review of the use frequency and clinical efficacy of TCM in treating PLC. Relevant literature from January 1, 2009, to January 1, 2021 was retrieved from network databases of China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, PubMed, and SinoMed. The most frequently used TCM and their efficacy in PLC treatment were summarized. Based on the inclusion and exclusion criteria, 33 articles were selected. Overall, the efficacy of the combination of TCM and Western medicines in the treatment of PLC was higher than that in the control groups (i.e. treatment with Western medicines alone) (65.11% vs. 44.31%, P < .05). Among the 33 selected articles, 11 were investigated for TCM preparation (marketed drugs) and 22 for TCM formulas. In total, 102 types of TCM (single herbs) were used to treat PLC. The top five most frequently used TCM were Poria (14.71%), Astragali radix (13.73%), Atractylodis Macrocephalae Rhizoma (12.75%), Bupleuri radix (12.75%), and Glycyrrhizae radix et Rhizoma (11.76%). Of the 102 types of TCM, tonics were the most frequently used categories, followed by heat-clearing medicines, blood-invigorating medicines, and stasis-resolving medicines. Of 207 papers, 174 (84.06%) could not be subjected to statistical analysis due to research quality. Further high-quality research on herb sources, formula components and dosage, toxicology, and ethics of TCM is necessary. In conclusion, TCM play a promising role in the treatment and management of PLC, although further investigations are warranted.http://www.sciencedirect.com/science/article/pii/S2095754821000442Traditional Chinese medicinesPrimary liver cancerIntegrative medicineClinical research |